Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Marce, S; Xicoy, B; Garcia, O; Cabezon, M; Estrada, N; Velez, P; Boque, C; Sagues, M; Angona, A; Teruel-Montoya, R; Ferrer-Marin, F; Amat, P; Hernandez-Boluda, JC; Ibarra, MM; Anguita, E; Cortes, M; Fernandez-Ruiz, A; Fontanals, S; Zamora, L; Grp Espanol Leucemia Mieloide Cron

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores:	Marce, S, Xicoy, B, Garcia, O, Cabezon, M, Estrada, N, Velez, P, Boque, C, Sagues, M, Angona, A, Teruel-Montoya, R, Ferrer-Marin, F, Amat, P, Hernandez-Boluda, JC, Ibarra, MM, Anguita, E, Cortes, M, Fernandez-Ruiz, A, Fontanals, S, Zamora, L, Grp Espanol Leucemia Mieloide Cron
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2021
País:	España
Institución:	INCLIVA
Repositorio:	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:	oai:incliva.fundanetsuite.com:p15867
Acceso en línea:	https://incliva.portalinvestigacion.com/publicaciones/15867
Access Level:	acceso abierto
Palabra clave:	BCR-ABL1 transcripts chronic myeloid leukemia discontinuation relapse-free survival response to imatinib survival

id	ES_adfa1909df59df03c6ed31423da84b7a
oai_identifier_str	oai:incliva.fundanetsuite.com:p15867
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.Marce, SXicoy, BGarcia, OCabezon, MEstrada, NVelez, PBoque, CSagues, MAngona, ATeruel-Montoya, RFerrer-Marin, FAmat, PHernandez-Boluda, JCIbarra, MMAnguita, ECortes, MFernandez-Ruiz, AFontanals, SZamora, LGrp Espanol Leucemia Mieloide CronBCR-ABL1 transcriptschronic myeloid leukemiadiscontinuationrelapse-free survivalresponse to imatinibsurvivalThe most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/15867Journal of Clinical MedicineISSN: 20770383reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p158672026-06-07T16:35:31Z
dc.title.none.fl_str_mv	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
title	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
spellingShingle	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Marce, S BCR-ABL1 transcripts chronic myeloid leukemia discontinuation relapse-free survival response to imatinib survival
title_short	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
title_full	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
title_fullStr	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
title_full_unstemmed	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
title_sort	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
dc.creator.none.fl_str_mv	Marce, S Xicoy, B Garcia, O Cabezon, M Estrada, N Velez, P Boque, C Sagues, M Angona, A Teruel-Montoya, R Ferrer-Marin, F Amat, P Hernandez-Boluda, JC Ibarra, MM Anguita, E Cortes, M Fernandez-Ruiz, A Fontanals, S Zamora, L Grp Espanol Leucemia Mieloide Cron
author	Marce, S
author_facet	Marce, S Xicoy, B Garcia, O Cabezon, M Estrada, N Velez, P Boque, C Sagues, M Angona, A Teruel-Montoya, R Ferrer-Marin, F Amat, P Hernandez-Boluda, JC Ibarra, MM Anguita, E Cortes, M Fernandez-Ruiz, A Fontanals, S Zamora, L Grp Espanol Leucemia Mieloide Cron
author_role	author
author2	Xicoy, B Garcia, O Cabezon, M Estrada, N Velez, P Boque, C Sagues, M Angona, A Teruel-Montoya, R Ferrer-Marin, F Amat, P Hernandez-Boluda, JC Ibarra, MM Anguita, E Cortes, M Fernandez-Ruiz, A Fontanals, S Zamora, L Grp Espanol Leucemia Mieloide Cron
author2_role	author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	BCR-ABL1 transcripts chronic myeloid leukemia discontinuation relapse-free survival response to imatinib survival
topic	BCR-ABL1 transcripts chronic myeloid leukemia discontinuation relapse-free survival response to imatinib survival
description	The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.
publishDate	2021
dc.date.none.fl_str_mv	2021
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://incliva.portalinvestigacion.com/publicaciones/15867
url	https://incliva.portalinvestigacion.com/publicaciones/15867
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	MDPI
publisher.none.fl_str_mv	MDPI
dc.source.none.fl_str_mv	Journal of Clinical Medicine ISSN: 20770383 reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname:INCLIVA
instname_str	INCLIVA
reponame_str	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection	r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869416503846109184
score	15,811543

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Similares en LA Referencia